Skip to main content
. Author manuscript; available in PMC: 2015 Sep 29.
Published in final edited form as: Pediatr Blood Cancer. 2012 Jun 28;59(5):902–907. doi: 10.1002/pbc.24207

Figure 2.

Figure 2

(A) Progression-free survival (PFS) and overall survival (OS) from the time of study enrollment of 33 patients with high-risk neuroblastoma. (B) PFS and OS from time of first HDC/SCR for 22 patients who underwent at least one HDC/SCR procedure. The number at risk at the start of year 2, 4, and 6 are given along the curves.